CellCarta
Anthony Mattacchione currently serves as the Chief Financial Officer at Caprion-HistoGenex, a position held since October 2020. Prior to this role, Anthony was the Senior Vice President and Chief Financial Officer at AMRI from April 2018 to May 2020 and at Bruker from February 2013 to April 2018, where responsibilities encompassed investor relations, corporate development, and financial planning. Before joining Bruker, Anthony held various financial leadership roles at MilliporeSigma and Gerber Scientific Inc., and began a career in finance as a Senior Auditor at PricewaterhouseCoopers. Anthony holds an MBA in Finance from the University of Connecticut and a BS in Accountancy from Central Connecticut State University.
This person is not in any offices
CellCarta
CellCarta's Mission is centered on collaborating and partnering with pharmaceutical and biotech companies through proteomics and immune monitoring enabling the acceleration of precision medicine in drug development.With a vision and deep understanding of the needs for complex immune monitoring in novel drug development, Caprion integratedImmuneCarta (formerly known as National Immune Monitoring), with its established and proven proteomics service, ProteoCarta. Together, Caprion now offers a fully integrated and unique service offering to its partners.